Compass Therapeutics (NASDAQ: CMPX) — Company Overview, News & Financial Data
Compass Therapeutics is a biotechnology firm focused on antibody therapeutics for cancer and autoimmune disorders.
Compass Therapeutics
Compass Therapeutics (NASDAQ:CMPX) is a biotechnology firm deeply immersed in the discovery and development of antibody therapeutics aimed at treating cancer, autoimmune disorders, and other diseases. The company leverages its proprietary StitchMabs™ and common light chain platforms to engineer novel biologic agents. Compass Therapeutics focuses on advancing its robust pipeline of therapeutic candidates, including lead assets that show promising preclinical and early clinical results for a range of medical conditions. The ultimate objective of Compass Therapeutics is to transform the landscape of treatment options available to patients suffering from severe diseases by bringing innovative and effective therapies to market.
Snapshot
Operations
Products and/or services of Compass Therapeutics
- CTx-471, a next-generation checkpoint inhibitor designed to stimulate the immune system to target and kill cancer cells.
- CTX-8371, a dual-action PI3K and HDAC inhibitor aimed at treating solid tumors.
- Patient-derived xenograft (PDX) models and in-house developed tumor cell lines for predictive efficacy testing and personalized medicine research.
Compass Therapeutics executive team
- Thomas J. SchuetzCEO & Vice Chairman
- Barry ShinChief Financial Officer
- Jonathan E. AndermanSenior VP, General Counsel & Corporate Secretary
- Neil L. LernerSenior VP & Chief Accounting Officer
- Bing GongChief Scientific Officer
- Anna GiffordSenior Manager of Communications & Chief of Staff
- Karin HerreraSenior VP & Head of Clinical Operations
- James KranzVP and Head of Chemistry Manufacturing & Controls
- Cynthia A. SirardChief Medical Officer
- Arjun PrasadChief Commercial Officer
Latest news about Compass Therapeutics
Key financials
Reported results for Compass Therapeutics, in USD.
- Market cap
- 138.2M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -72.8M | -66.5M | |
| 850K | -56.6M | -49.4M | |
| 0 | -50.4M | -42.5M | |
| 0 | -41.7M | -39.2M |